segment and potentially posterior segment signs. These findings suggest that units treating TB should actively screen all patients newly presenting with TB for occult ocular disease.

Abstract P169 Table 1 Uveitis symptoms relating to TB status

	Active patients—latent patient response difference: (95% CI)	p-Value*	Active patients (TB-HIV)—active patient (TB) response difference: (95% CI)	p-Value*
Redness	31.5% (–10% to 60%)	0.236	–21.3% (–40% to 50%)	1.000
Pain	46.9% (10% to 70%)	0.033	–21.3% (–40% to 50%)	1.000
Itchiness	37.8% (0% to 70%)	0.033	21.2% (–30% to 60%)	1.000
Watery	55.9% (20% to 80%)	0.004	3.1% (–50% to 40%)	1.000
Light sensitivity	30.1% (–10% to 60%)	0.209	–12.2% (–50% to 40%)	1.000
Visual disturbance	2.8% (–30% to 30%)	1.000	15.1% (–20% to 30%)	1.000
Loss of vision	9.1% (–10% to 40%)	1.000	–9.1% (–40% to 50%)	1.000
Floater	27.3% (0% to 60%)	0.041	39.4% (–20% to 70%)	1.000

*Fisher exact significance (two-sided).

P170 TB-HIV CO-INFECTION: HOW DOES THE UK COMPARE TO EUROPE?

doi:10.1136/thx.2010.151043.21

¹M E Kruijshaar, ¹L Pimpin, ²C Ködmön, ³M Lipman, ¹V Delpech, ¹B Rice, ⁴L Drumright, ²D Manissero, ¹I Abubakar. ¹Health Protection Agency – Centre for Infections, London, UK; ²European Centre for Disease Prevention and Control, Stockholm, Sweden; ³Royal Free Hospital – Respiratory Medicine, London, UK; ⁴Imperial College, London, UK

Background Tuberculosis (TB) and HIV/AIDS are global public health problems with considerable mutual interaction. Data on national TB-HIV co-infection trends are essential to plan and evaluate TB-HIV control measures. We compared the burden of co-infection and how this is monitored in surveillance systems in England with the rest of Europe.

Methods

- ▶ A systematic search of academic and grey literature identifying studies reporting data on TB-HIV co-infection in EU/EEA countries.
- ▶ A questionnaire survey among EU/EEA countries' TB surveillance leads, regarding surveillance methods, data and proportion of cases tested for HIV.
- ▶ For England, Wales and Northern Ireland, cases reported to Enhanced Tuberculosis Surveillance matched to national HIV/AIDS case reports.

Results A total of 55 papers were identified providing estimates on the proportion of TB patients co-infected with HIV. From 30 EU/EEA countries 25 TB questionnaires were returned. This gave prevalence data for 23 countries. In England, the prevalence of HIV co-infection among TB patients rose from 5% in 2000 to 8% in 2005, with a peak at 9% in 2003–2004. These figures are at the higher end of what is observed in Europe. France, Iceland and Portugal (11–15%) had higher co-infection levels, while similar levels were found for Estonia and Malta (9%). Very low levels were reported from central European countries (0–1%). A rise in co-infection levels was seen in Estonia, Latvia, Lithuania, the UK and Belgium, while decreases were seen in Spain and Portugal. The burden was higher in countries reporting high levels of HIV testing and countries with a higher HIV burden. Information on TB patients' HIV status was collected in 19/25 TB surveillance systems responding to the survey. While 17 countries rely on clinician reporting, in England and Finland, data are obtained by matching to national HIV/AIDS surveillance data due to confidentiality concerns.

Conclusion Levels of TB-HIV co-infection vary widely across EU countries, with the UK being at the higher end. Our data suggest that TB-HIV surveillance appears patchy and needs strengthening to better inform control policies and clinical practice.

P171 THE DEVELOPMENT OF A UK NATIONAL MDRTB SERVICE

doi:10.1136/thx.2010.151043.22

P D O Davies, D M Cullen. *TB Unit, Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, UK*

Introduction The low incidence in the UK means that few specialists treating tuberculosis have much experience of managing patients with MDRTB. To attempt to overcome this gap, the MDRTB Service was established at the Liverpool Heart and Chest Hospital in January 2008.

Method The service offers ready access to expert advice on the management of patients with MDRTB via an electronic virtual committee of TB experts. The advice given offers the likely best treatment for patients and by doing so prevents the emergence of Extreme drug resistant TB (XDRTB). The second function of the Service is to collect data on all MDRTB cases identified in the UK and record outcomes.

Results From 2008, the MDRTB Service has been approached for advice on 93 TB cases. Of these 70 were confirmed as MDR and 6 XDRTB whilst the remainder either could not be confirmed as MDR, were Isoniazid OR Rifampicin mono resistant or were more general requests for advice. The initial resistant patterns of 76 MDRTB cases showed resistance to Isoniazid and Rifampicin, 52% of the cases were resistant to Streptomycin, 41% to Ethambutol and 31% to Pyrazinamide. Indeed 33% of cases were resistant to three Group 1 drugs and 29% to 4 drugs in this category. In the 6 XDRTB patients, three were resistant to one group 2 drug only whilst the other three cases were resistant to more than one group 2 drug. All XDRTB cases were resistant to more than one group 3 drug, and 3 (50%) had more than one resistance in both drug groups. Patients of non-UK origin accounted for 86% of cases (male: 48%) of which 5 (8%) were XDR-TB, the rest MDR-TB. India (28%) and Sub Saharan Africa (26%) were the most prevalent countries of origin. 57% of patients had pulmonary disease, of which 82% were known to be sputum smear positive and therefore infectious. Three patients are known to have died and the rest are continuing on treatment.

Conclusion The MDRTB service is an important means of providing expert advice on management of these cases. Streptomycin resistance was present in the majority.

Therapeutic interventions in asthma and airways disease

P172 FLUTICASONE/SALMETEROL COMBINATION CONFERS SIGNIFICANT BENEFITS IN SMOKING ASTHMATICS

doi:10.1136/thx.2010.151043.23

K L Clearie, L McKinlay, P A Williamson, P Hopkinson, K T Meldrum, B J Lipworth. *Asthma and allergy research group, University of Dundee, Dundee, UK*

Rationale Smoking is known to increase airway inflammation and induce relative resistance to of inhaled steroids.

Objectives This study aimed to evaluate the effects of adding salmeterol to fluticasone (FPSM) versus doubling the dose of fluticasone (FP) in smoking and non-smoking asthmatics.

Methods 16 non-smoking and 15 smoking asthmatics were randomised to completion in a double blind, placebo-controlled crossover study. They received either FP/SM pMDI (125/25 mg) two puffs bid (+FP placebo) or active FP 250 mg pMDI two puffs bid (+FPSM placebo), for 2 weeks each, with baselines after 1–2 week run-in and wash-out periods. The primary outcome was change from baseline in methacholine PC₂₀.

Results In non-smokers there were similar improvements with FP and FPSM. Smokers demonstrated no change in methacholine PC₂₀ following treatment with FP, however FPSM conferred significant benefit: 1.6 doubling dilution (95% CI 1.0 to 2.2), p<0.01. Smokers